HSDT - הכנסה תפעולית לפני ניכוי פחת Helius Medical Technologies

Helius Medical (HSDT) demonstrates weak operational momentum, requiring constant capital injections. The development of portable systems for stroke rehabilitation and the expansion of testing for other pathologies mitigate overall risks. The current EBITDA_Co level confirms profit dynamics, where the value 0.00 represents the current metric. The company's revenues are based on the sale of PoNS stimulators for the restoration of patients' neural connections.

This metric captures the daily cash balance of operating income, reflecting the real balance of supply and demand excluding depreciation factors. By analyzing the EBITDA statistics of Helius Medical (HSDT), an investor can assess the scaling efficiency of PoNS systems in US clinics; however, one must distinguish between temporary liquidity spikes and the long-term business growth trend of Helius Medical to avoid overpaying for the asset.